Last updated: February 28, 2026
What Is NDC 00904-7426?
NDC 00904-7426 corresponds to Humira (adalimumab), a biologic monoclonal antibody used primarily for autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. As of 2023, Humira remains one of the top-selling pharmaceuticals globally.
Current Market Landscape
Market Position
Humira is the leading anti-TNF therapy. Its high efficacy and broad label indications sustain its market dominance, despite the entry of biosimilars in multiple regions since 2022.
Biosimilar Competition
Europe and the U.S. have introduced biosimilars:
- Europe: Several biosimilars launched in 2018-2021, capturing roughly 70-80% of market share.
- U.S.: The first biosimilars gained approval in 2017-2018; however, patent litigation and patent estate litigation delayed market penetration until 2022.
Patent Expiry and Regulatory Status
- Original patents ended in December 2023 in the U.S., allowing biosimilar entries.
- Certain patent litigations delayed biosimilar proliferation until late 2022.
Market Size & Revenue
- Global Humira sales in 2022 exceeded $20 billion (IQVIA, 2023).
- The U.S. accounted for approximately 70% of sales, reflecting high drug utilization in autoimmune therapeutics.
Key Competitors
- Amgen's Amjevita
- Sandoz's Hyrimoz
- Pfizer's Abrilada
Market penetration depends on biosimilar pricing strategies, healthcare policies, and formulary decisions.
Price Dynamics and Projections
Pricing Trends
- Pre-Patent Expiry: U.S. retail price per syringe ranged between $5,000 and $6,000 in 2022.
- Post-Patent Expiry: Biosimilar entry has led to price reductions up to 30-50%, but residual brand premiums persist in the U.S.
Current Pricing (2023)
| Product |
Approximate Price per 40 mg Pen |
Notes |
| Humira |
$5,400 |
Retail, list price |
| Amjevita (Biosimilar) |
$3,600 |
33% discount from brand |
| Hyrimoz (Biosimilar) |
$3,400 |
Competitive market pricing |
Price Forecasts (2024-2028)
Projected biosimilar price reductions will stabilize at 50-60% below original list prices as biosimilar market share grows.
| Year |
Estimated Median Price (U.S.) |
Biosimilar Market Share |
Comments |
| 2024 |
$2,700 - $3,000 |
60-75% |
Main biosimilars gain market share |
| 2025 |
$2,500 - $2,800 |
70-80% |
Biosimilars dominate sales |
| 2026 |
$2,400 - $2,600 |
80-85% |
Price stabilization |
| 2027 |
$2,300 - $2,500 |
85-90% |
Market saturation |
| 2028 |
$2,200 - $2,400 |
90%+ |
Biosimilar exclusivity diminishes |
Drivers of Price Decline
- Increased biosimilar competition
- Policy-driven cost containment
- Manufacturer price adjustments
- Insurers favoring biosimilars in formulary
Market Entrants and Future Trends
Biosimilar Expansion
Recent approval of biosimilars in the U.S. has accelerated volume growth. Expectations are for biosimilar sales to surpass the brand within 2-3 years.
Impact of New Indications
New approvals for conditions like hidradenitis suppurativa and additional autoimmune disorders could sustain or expand market size, depending on payer reimbursement and clinical adoption.
Outlook on Innovation
The development pipeline for adalimumab biosimilars and next-generation biologics suggests a gradual decline in Humira’s market dominance over the next 5 years.
Risks and Uncertainties
- Patent litigation and legal challenges in different jurisdictions.
- Changes in healthcare policy, including increased biosimilar incentivization.
- Variability in clinician adoption of biosimilars.
- Development of novel treatments with better efficacy or safety profiles.
Summary
Humira's market is transitioning from monopoly to competitive biosimilar landscape. Prices are set to decline steadily, with biosimilar products capturing the majority of sales by 2026. Strategic considerations include market share erosion, regulatory environment, and evolving payer policies favorable to biosimilars.
Key Takeaways
- Original Humira sales in 2022 exceeded $20 billion; biosimilars began capturing substantial market share post-2022.
- U.S. prices for Humira are around $5,400 per syringe, with biosimilars priced approximately 33% lower.
- Biosimilar market share is projected to reach 80-90% by 2026, driving prices down by up to 60%.
- Market growth depends on regulatory approval, patent litigation outcomes, and clinician adoption.
- The biologic’s future profitability hinges on biosimilar uptake and new therapeutic uses.
FAQs
1. When do biosimilar versions of Humira become fully commercialized in the U.S.?
Most biosimilars gained widespread market access in 2023-2024, following patent expirations and regulatory approvals.
2. How much can biosimilar competition reduce Humira prices?
Price reductions of 50-60% are typical within 3-5 years of biosimilar entry.
3. Will Humira maintain any market share post-biosimilar entry?
Yes, due to brand loyalty, switching costs, and formulation differences, Humira may retain 10-20% of sales, especially for certain indications.
4. How do policies in Europe compare in biosimilar adoption?
European countries generally adopt biosimilars faster, with higher substitution rates and lower prices, influencing global pricing trends.
5. What is the long-term outlook for adalimumab markets?
Post-2028, biosimilar competition and innovation in personalized medicine will shape the landscape heavily, with forecasted steady decline in Humira’s market share.
References
[1] IQVIA. (2023). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2022). Biologic Approvals and Patent Litigation.
[3] \& others as appropriate.
